SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
50128Nice call by Meryl Witmer in Saturday’s Barron’s: barrons.comDewDiligence_on_SI17/16/2018
50127Indivior's shares soar 33 percent after U.S. court blocks sale of rival geneA.J. Mullen-7/16/2018
50126I agree - but timing is still quite murky because of how the reimbursement systeBiomaven27/15/2018
50125China sales of roxadustat could be huge, by itself, for reasons unique to China Biotech Jim27/15/2018
50124Well roxa is completely partnered, so it's all royalties and so marketing coBiomaven-7/14/2018
50123No data yet. The comments on eGFR were made in the two most recent presentationsBiomaven37/14/2018
50122<Neff's unsolicited comment about bending the eGFR curve was very signifiBiotech Jim-7/14/2018
50121If Roxa were "ginormous" with little marketing costs, they could send JamesK-7/14/2018
50120To some extent I think the same happened with ponatinib. If you aggressively looBiomaven17/13/2018
50119Apropos to #49583: forbes.comDewDiligence_on_SI-7/13/2018
50118Herpes linked to Alzheimer's: Antivirals may help When the Taiwanese authorbiocqr17/13/2018
50117I was planning to not add anything more for a bit, other than to answer question31Floors-7/13/2018
50116OT OT This is clearly off-topic and political, though not directed, per se, at Pquidditch17/13/2018
50115Appreciate your comment Biomaven, thank you. IF this triples in 12 months, whic31Floors-7/12/2018
50114Lol - what happens when I get carried away.Biomaven-7/12/2018
50113The word, ginormous warrants an automatic ban on my board, but I suppose things DewDiligence_on_SI-7/12/2018
50112I think that is probably about right. Maybe they partner some territories like JBiomaven37/12/2018
50111Pretty much nobody here invests in Canadian nanocaps. The world is never likely Biomaven-7/12/2018
50110Ligand continues to ROCK. If you've read my IPA posts, particularly the las31Floors-7/12/2018
50109Post the PEGS Boston conference IPA is in discussions with potential customers, 31Floors-7/11/2018
50108Just published today in Nature: Letter | Published: 11 July 2018 ReprogrammingArt Bechhoefer-7/11/2018
50107IPA. It is a shame that the week after week selling by ONE director GC is havin31Floors-7/11/2018
50106Indivior Sees FY 2018 Net Revenue and Adjusted Net Income Below Previous ExpectaA.J. Mullen-7/11/2018
50105Complexities in G-Protein Couple Receptors (GPCRs), and in GPCR signalling via pBiotech Jim-7/8/2018
50104I see things bit differently, but as Ashley said,....it is too complicated.... tMiljenko Zuanic-7/6/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News